ArticleSAGE open medicine2025
SNHG19 promotes the proliferation and metastasis of hepatocellular carcinoma through regulating the miR-137/protein tyrosine phosphatase 4A3 axis.
Article in SAGE open medicine, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- microRNAs Regulate Cellular Magnesium by Tuning Expression of the Plasma Membrane Protein CNNM4.ACS chemical biology · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Objectives: Long noncoding RNAs plays the important part in tumor biology. SNHG19 was found to be a new oncogenic lncRNA in some malignant tumors. However, the effect of SNHG19 in hepatocellular carcinoma has not been reported. Methods: The expression of SNHG19 in hepatocellular carcinoma tissues were detected by using quantitative Real-Time Reverse Transcription Polymerase Chain Reaction (qRT-PCR). Melanoma cases from The Cancer Genome Atlas were included in this study. cell counting kit-8 assay, Transwell, and scratch wound assay were used to explore the role of SNHG19 in melanoma cells. Luciferase reporter assays and RNA pull-down assay were used to explore the molecular mechanism of SNHG19 in hepatocellular carcinoma. Results: Here, we found that SNHG19 level was upregulated in hepatocellular carcinoma. Hepatocellular carcinoma patients with high levels of SNHG19 have shorter Disease-Free Survival (RFS). SNHG19 promotes the Protein Tyrosine Phosphatase 4A3 expression by sponging miR-137 to liberate Protein Tyrosine Phosphatase 4A3 mRNA transcripts. SNHG19 enhances the development of hepatocellular carcinoma by affecting miR-137/Protein Tyrosine Phosphatase 4A3 axis. Conclusion: These results demonstrated the effect of SNHG19 in the occurrence and progression of hepatocellular carcinoma. SNHG19 may be used as the specific molecular target in patients with hepatocellular carcinoma.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.